$8.59
Grifols SA ADR is a drug manufacturers - general business based in the US. Grifols SA ADR shares (GRFS) are listed on the NASDAQ and all prices are listed in US Dollars. Grifols SA ADR employs 23,505 staff and has a trailing 12-month revenue of around $6.8 billion.
What's in this guide?
Our top picks for where to buy Grifols SA ADR stock
How to buy Grifols SA ADR stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – GRFS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Grifols SA ADR stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Grifols SA ADR stock price (NASDAQ: GRFS)
Use our graph to track the performance of GRFS stocks over time.Grifols SA ADR shares at a glance
Latest market close | $8.88 |
---|---|
52-week range | $5.30 - $12.15 |
50-day moving average | $7.67 |
200-day moving average | $7.89 |
Wall St. target price | $11.49 |
PE ratio | 34.5926 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.27 |
Is it a good time to buy Grifols SA ADR stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Grifols SA ADR price performance over time
Historical closes compared with the close of $8.88 from 2024-09-05
1 week (2024-08-30) | -4.93% |
---|---|
1 month (2024-08-06) | 22.65% |
3 months (2024-06-06) | 18.24% |
6 months (2024-03-06) | 62.34% |
1 year (2023-09-06) | -3.27% |
---|---|
2 years (2022-09-06) | 16.84% |
3 years (2021-09-03) | 14.72 |
5 years (2019-09-06) | 19.9817 |
Is Grifols SA ADR stock undervalued or overvalued?
Valuing Grifols SA ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Grifols SA ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Grifols SA ADR's P/E ratio
Grifols SA ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Grifols SA ADR shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Grifols SA ADR's PEG ratio
Grifols SA ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2982. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Grifols SA ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Grifols SA ADR's EBITDA
Grifols SA ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a Grifols SA ADR's overall financial performance and is widely used to measure a its profitability.
Grifols SA ADR financials
Revenue TTM | $6.8 billion |
---|---|
Operating margin TTM | 16.19% |
Gross profit TTM | $2.2 billion |
Return on assets TTM | 2.47% |
Return on equity TTM | 2.82% |
Profit margin | 2.43% |
Book value | $8.23 |
Market Capitalization | $7.1 billion |
TTM: trailing 12 months
Grifols SA ADR share dividends
We're not expecting Grifols SA ADR to pay a dividend over the next 12 months.
Have Grifols SA ADR's shares ever split?
Grifols SA ADR's shares were split on a 2:1 basis on 3 January 2016. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Grifols SA ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Grifols SA ADR shares which in turn could have impacted Grifols SA ADR's share price.
Grifols SA ADR share price volatility
Over the last 12 months, Grifols SA ADR's shares have ranged in value from as little as $5.3001 up to $12.1499. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Grifols SA ADR's is 0.722. This would suggest that Grifols SA ADR's shares are less volatile than average (for this exchange).
Grifols SA ADR overview
Grifols, S. A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development.
Frequently asked questions
What percentage of Grifols SA ADR is owned by institutions?Currently 57.85% of Grifols SA ADR shares are held by institutions. How many people work for Grifols SA ADR?
Latest data suggests 23,505 work at Grifols SA ADR. When does the fiscal year end for Grifols SA ADR?
Grifols SA ADR's fiscal year ends in December. Where is Grifols SA ADR based?
Grifols SA ADR's address is: Avinguda de la Generalitat, 152, Barcelona, Spain, 08174 What is Grifols SA ADR's ISIN number?
Grifols SA ADR's international securities identification number is: US3984384087 What is Grifols SA ADR's CUSIP number?
Grifols SA ADR's Committee on Uniform Securities Identification Procedures number is: 398438200
More guides on Finder
-
How to buy Zentek stock (ZTEK)
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
-
How to buy Mainz Biomed stock (Mainz Biomed)
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
-
How to buy ATAI Life Sciences stock (Atai Life Sciences)
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
-
How to buy Owlet Baby Care stock (Owlet Baby Care)
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
-
How to buy Eli Lilly and Company stock (LLY)
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
-
How to buy Humana stock (HUM)
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
-
How to buy Illumina stock (ILMN)
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
-
How to buy UnitedHealth Group Incorporated stock (UNH)
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
-
How to buy Pfizer stock (PFE)
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
-
How to buy Johnson & Johnson stock (JNJ)
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Ask a question